text
"['\n3. 원재료 및 생산설비\n가. 주요 원재료 등의 현황 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0(단위 : 천원 %)\n사업부문\n매입유형\n품 \xa0 목\n구체적용도\n매입액\n비율\n비 고\n의약품\n원재료\nEPINASTINE.HBr\xa0\n에피나스틴\n4,147,200\xa0\n10.5\nCEFMETAZOLE-A\n세프메타졸\n2,618,700\xa0\n6.6\nBERAPROST SODIUM\n베리실정\n2,126,834\xa0\n5.4\n론서프 정 20mg 1 T\n론서프정\n2,073,237\xa0\n5.2\nCRUDE EPINASTINE\n에피나스틴\n2,017,353\xa0\n5.1\nCRUDE MEROPENEM kg\n메로페넴\n1,968,829\xa0\n5.0\nLANSOPRAZOLE PELLETS(IRELAND)\n란스톤정\n1,936,233\xa0\n4.9\nTIANEPTINE SOD\n스타브론정\n1,710,974\xa0\n4.3\nCEFDINIR\n옴니세프\n1,704,772\xa0\n4.3\nVARENICLINE SALICYLATE\n니코챔스 정외\n1,350,000\xa0\n3.4\nCRUDE-MEROPENEM\n메로페넴(수출)\n1,324,617\xa0\n3.4\n기타\n\u3000\n16,519,714\xa0\n41.9\n합 \xa0 \xa0계\n\u3000\n39,498,463\xa0\n100.0\n부재료\nCHITOSAN\n무코스타 서방정\n\xa0566,775\xa0\n11.1\nAMINO METHACRYLATE COPOLYMER(EUDRAGIT EPO)\n무코스타 서방정\n\xa0318,700\xa0\n6.3\nE.A(CF)\n에피나스틴 외\n\xa0238,896\xa0\n4.7\nMEGLUMINE(USP)\n티오메타정\n\xa0227,500\xa0\n4.5\nROSUVASTATIN CALCIUM\n로스바스틴\n189,500\xa0\n3.7\nN-HEXANE\n에피나스틴\n\xa0188,147\xa0\n3.7\nNAI(SODIUM IODIDE)\n세프디토렌\n\xa0 183,800\xa0\n3.6\n기타\n\u3000\n\xa03,173,451\xa0\n62.4\n합 \xa0 \xa0계\n\u3000\n5,086,769\xa0\n100.0\n포장재료\nACLAR FILM(0.329*232mm)(200m)\n니코챔스 정외\n437,029\xa0\n14.0\n테프론 고무마개(W2T32-B1-S)\n크라비트 주외\n338,688\xa0\n10.9\nCRAVIT INJ 750mg VIAL(150mL)\n크라비트 주외\n157,568\xa0\n5.1\nALU-ALU FILM(230mm*300)\n리피토플러스외\n106,505\xa0\n3.4\n무색 VIAL(φ30,60mm)\n뉴로페넴 주외\n104,768\xa0\n3.4\n기타\n\u3000\n1,968,818\xa0\n63.2\n합 \xa0 \xa0계\n\u3000\n3,113,376\xa0\n100.0\n총 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0계\n47,698,608\xa0\n제일헬스사이언스(주) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 (단위 : 천원 %)\n회사\n매입유형\n품목\n구체적용도\n매입액\n비율\n비고\n제일헬스사이언스(주)\n원료\nKETOPROFEN(ZHEJIANG)\n케펜텍\n244,000\n4.9\n원료\nKETOPROFEN\n케펜텍\n445,050\n2.7\n원료\nKEFEN TECH 린트포(수출용)\n케펜텍\n1,755,963\n19.5\n원료\nKEFEN TECH 린트포\n케펜텍\n663,681\n9.7\n원료\nUNITAC-A700\n케펜텍\n885,600\n7.3\n포장재료\nPAP 밀착포(공용)\n케펜텍 외\n253,350\n2.8\n\u3000\n기타\n4,859,970\n53.1\n합계\n9,127,614\n100.0\n(가). 주요 원재료 등의 가격변동추이\n제일약품(주) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 (단위: 원)\n품 \xa0목\n제6기 분기\n제5기\n제4기\nEPINASTINE.HBr\xa0\n1,200,000\n1,100,000\n1,100,000\nLANSOPRAZOLE PELLETS\n870,217\n918,771\n957,023\nBERAPROST SODIUM\n5,656,475\n5,621,729\n6,273,078\nROSUVASTATIN CALCIUM\n2,105,556\n2,478,125\n2,500,000\nROSUVASTATIN PMB t-BUTYL ESTER\n1,430,160\n1,377,243\n1,438,476\n테프론 고무마개(W2T32-B1-S)\n420\n420\n420\n(1)산출기준 : 평균구입가격 표시(2)주요가격변동 원인 : 환율변동 및 원료비 단가변동 제일헬스사이언스(주) \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0(단위: 원)\n품 \xa0목\n제7기 분기\n제6기\n제5기\nKETOPROFEN\n138,000\n95,182\n91,053\nKEFEN TECH 린트포(수출용)\n3,260\n3,260\n-\nUNITAC-A700\n8,200\n8,200\n8,200\nKEFEN TECH AL원단(수출용)\n495\n292\n282\n(1)산출기준 : 평균구입가격 표시(2)주요가격변동 원인 : 환율변동 및 원료비 단가변동\n나. 생산 및 설비에 관한 사항[지배회사] 제일파마홀딩스(주)(가). 생산설비의 현황 등\r\n당사는 분할 후 지주회사로 전환하여 별도의 생산시설이 없습니다.\n[종속회사] 제일약품(주)\n가). 생산능력 및 생산능력의 산출근거\n\xa0 (1) 생산능력\n품 \xa0목\n단위\n구 분 /\xa0\n규 격\n2022년(제6기분기)\n2021년(제5기)\n2020년(제4기)\n정제\n정\n36\xa0\n\xa0 \xa0 \xa0 143,078,400\xa0\n\xa0 \xa0 \xa0190,771,200\xa0\n\xa0 \xa0 \xa0190,771,200\xa0\n36\xa0\n\xa0 \xa0 \xa0 214,617,600\xa0\n\xa0 \xa0 \xa0286,156,800\xa0\n\xa0 \xa0 \xa0286,156,800\xa0\n32\xa0\n\xa0 \xa0 \xa0 \xa099,532,800\xa0\n\xa0 \xa0 \xa0132,710,400\xa0\n\xa0 \xa0 \xa0132,710,400\xa0\n39\n\xa0 \xa0 \xa0 286,416,000\xa0\n\xa0 \xa0 \xa0381,888,000\xa0\n\xa0 \xa0 \xa0381,888,000\xa0\n캡슐제\n정\n36\xa0\n\xa0 \xa0 \xa0 111,974,400\xa0\n\xa0 \xa0 \xa0149,299,200\xa0\n\xa0 \xa0 \xa0149,299,200\xa0\n34\xa0\n\xa0 \xa0 \xa0 99,878,400\xa0\n\xa0 \xa0 \xa0133,171,200\xa0\n\xa0 \xa0 \xa0133,171,200\xa0\n56\xa0\n\xa0 \xa0 \xa0270,950,400\xa0\n\xa0 \xa0 \xa0361,267,200\xa0\n\xa0 \xa0 \xa0361,267,200\xa0\n주사제\n바이알\n-\n\xa0 \xa0 \xa0 \xa0 864,000\xa0\n\xa0 \xa0 \xa0 \xa0 1,152,000\xa0\n\xa0 \xa0 \xa0 \xa0 1,152,000\xa0\n합성원료\nkg\n라인1\n\xa0 \xa0 \xa0 \xa0 \xa04,500\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 6,000\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 6,000\xa0\n라인2\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa06755\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0900\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0900\xa0\n세파일반\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 3,000\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 4,000\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 4,000\xa0\n세파무균\n\xa0 \xa0 \xa0 \xa0 \xa0 7,500\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa010,000\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa010,000\xa0\n페넴무균\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa010,500\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 14,000\xa0\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 14,000\xa0\n\xa0 \xa0(2). 산출기준 및 산출방법 등\n - 산출기준\n주요 생산 설비의 기본수용력을 기준으로 작성되었습니다.\xa0\n구 \xa0분\n(단위)\n규격(발수)\n최대속도\n(RPM)\n표준속도\n(RPM)\n시간당 최대\n시간당 표준\n연간최대\n연간표준\n정제\n(정)\n36\xa0\n70\xa0\n46\xa0\n151,200\xa0\n99,360\xa0\n290,304,000\xa0\n190,771,200\xa0\n36\xa0\n70\xa0\n69\xa0\n151,200\xa0\n149,040\xa0\n290,304,000\xa0\n286,156,800\xa0\n32\xa0\n50\xa0\n36\xa0\n96,000\xa0\n69,120\xa0\n184,320,000\xa0\n132,710,400\xa0\n39\xa0\n90\xa0\n85\xa0\n210,600\xa0\n198,900\xa0\n404,352,000\xa0\n381,888,000\xa0\n캡슐제\n(정)\n36\xa0\n50\xa0\n36\xa0\n108,000\xa0\n77,760\xa0\n207,360,000\xa0\n149,299,200\xa0\n34\xa0\n52\xa0\n34\xa0\n106,080\xa0\n69,360\xa0\n203,673,600\xa0\n133,171,200\xa0\n56\xa0\n125\xa0\n56\xa0\n420,000\xa0\n188,160\xa0\n806,400,000\xa0\n361,267,200\xa0\n주사제\n(바이알)\n1일4시간1주4일 가동\n1,200\xa0\n1,200\xa0\n1,200\xa0\n1,200\xa0\n2,304,000\xa0\n1,152,000\xa0\n품목\n구분\n산출량\n연간사이클수\n연속\n연간최대\n합성원료(kg)\n라인1\n50\n120\n1\n6,000\n라인2\n2.5\n120\n3\n900\n세파일반\n40\n50\n2\n4,000\n세파무균\n100\n50\n2\n10,000\n페넴무균\n140\n50\n2\n14,000\n합 \xa0 \xa0 \xa0계\n34,900\n- 산출방법\n품 \xa0목\n산 출 방 법\n정제, 캡슐제\n연간표준 = 규격발수 X 표준속도 X 8시간 X 240일\n주사제\n연간표준 = 시간당 표준 \xa0X 4시간 X 240일\n합성원료\n연간최대 = 산출량 X 연간사이클수 X \xa0연속수\n평균가동일수*8시간(일일작업시간)*시간당 생산능력- 평균가동시간\n일평균 가동시간 : 8시간 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0월평균 가동시간 : 20일(160시간)연평균가동시간 \xa0: 240일(1,920시간)\n나). 생산실적 및 가동률\n(1) 생산실적\n(단위 : 천원 )\n사업부문\n품목\n사업소\n제6기 분기\n제5기\n제4기\n의약품제 \xa0 조\n베라실 정\n2,351,705\n4,261,065\n4,970,389\n티에스원캅셀\n2,428,782\n2,928,924\n3,790,071\n란스톤캅셀\n3,039,017\n3,861,156\n3,896,692\n야마테탄 주\n1,431,411\n1,508,588\n2,927,043\n스타브론 정\n2,279,965\n3,166,217\n3,491,033\n옴니세프\xa0\n1,670,632\n1,359,910\n853,020\n크라비트주\n2,490,170\n2,405,291\n2,982,467\n넥실렌정\n1,937,843\n3,205,996\n3,944,080\n가스트렉스 과립\n1,689,252\n1,591,808\n1,768,139\n론서프정\n2,112,253\n1,863,298\n1,369,427\n리피토플러스\n2,756,243\n2,050,237\n0\n기타\n44,686,889\n53,263,457\n60,735,680\n합 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 계\n68,874,162\n81,465,947\n90,728,041\n(2) 당해 사업연도의 가동률\n(단위 : 시간)\n사업소(사업부문)\n가동가능시간\n실제가동시간\n평균가동률\n의약품제조\n1,440\n937\n65.07\n합 계\n1,440\n937\n65.07\n[종속회사] 제일헬스사이언스(주)가). 생산능력 및 생산능력의 산출근거\n\xa0(1) 생산능력\n품 \xa0목\n단위\n구 분 /\xa0\n규 격\n2022.1.1~9.30\n(제7기 분기)\n2021.1.1~12.31\n(제6기)\n2020.1.1~12.31\n(제5기)\n카타플라스마제\nsh\n422매/분+396매/분\n60,177,600\n86,486,400\xa0\n86,486,400\xa0\n플라스타제\nsh\n1050매/분+1050매/분+420/분\n190,512,000\n241,920,000\xa0\n241,920,000\xa0\n 2) 산출기준 및 산출방법 등\n\xa0 - 산출기준\n주요 생산 설비의 기본수용력을 기준으로 작성되었습니다.\xa0\n구 \xa0분\n(단위)\n규격(발수)\n최대속도\n(RPM)\n표준속도\n(RPM)\n시간당 최대\n시간당 표준\n연간최대\n연간표준\n카타플라스마제\n422매/분+396매/분\n8시간/1일\n7시간/1일\n\u3000\n91,699,200\n80,236,800\n플라스타제\n1050매/분+1050매/분+420/분\n8시간/1일\n7시간/1일\n\u3000\n290,304,000\n254,016,000\n\xa0- 산출방법\n품 \xa0목\n산 출 방 법\n카타플라스마,플라스타\n연간표준 = 규격 X 7시간 X 240일\n평균가동일수*8시간(일일작업시간)*시간당 생산능력 - 평균가동시간\n일평균 가동시간 : 8시간 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0월평균 가동시간 : 20일(160시간)연평균가동시간 \xa0: 240일(1,920시간)\n나). 생산실적 및 가동률\n(1) 생산실적\n(단위 : 천원 )\n회사\n품목\n사업소\n2022.1.1~9.30\n(제7기 분기)\n2021.1.1~12.31\n(제6기)\n2020.1.1~12.31\n(제5기)\n제일헬스사이언스(주)\n케펜텍\n8,187,363\n7,402,061\n7,705,129\n쿨파프\n2,527,380\n207,426\n3,688,312\n핫파프\n209,829\n-\n140,325\n기타\n1,693,386\n859,312\n1,432,523\n합 \xa0 \xa0계\n12,617,958\n8,468,799\n12,966,289\n\xa0\xa0\n(2) 당해 사업연도의 가동률\n(단위 : 시간)\n사업소(사업부문)\n가동가능시간\n실제가동시간\n평균가동률\n의약품제조\n1,440\n933\n64.79\n합 계\n1,440\n933\n64.79\n(나). 생산설비의 현황 등\n[종속기업-제일약품(주)](1) 생산설비의 현황\n(단위 : ㎡,천원 )\n자산항목\n소유형태\n소재지\n기초장부가액\n당기증감\n당기상각\n기말장부가액\n비고\n증가\n감소\n토지\n자가\n용인\n27,148,806\n27,148,806\n건물\n자가\n용인\n64,674,863\n988,854\n63,686,009\n구축물\n자가\n용인\n24,780\n21,846\n2,934\n기계장치\n자가\n용인\n5,806,666\n3,990,667\n4\n1,727,332\n8,069,997\n차량운반구\n자가\n용인\n13,808\n7,293\n6,515\n공구기구\n자가\n용인\n1,023,515\n705,854\n2\n392,513\n1,336,854\n집기비품\n자가\n용인\n474,734\n206,621\n118,742\n562,613\n시설물\n자가\n용인\n5,914,363\n72,500\n787,712\n5,199,151\n합계\n105,081,535\n4,975,642\n6\n4,044,292\n106,012,879\n(2) 설비의 신설ㆍ매입 계획 등\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 (단위 : 억원)\n자산항목\n소재지\n매입예정금액\n비고\n토지\n용인\n100\n공장용지매입\n[종속기업-제일헬스사이언스(주)](1) 생산설비의 현황\n(단위 : ㎡,천원 )\n자산항목\n소유형태\n소재지\n기초장부가액\n당기증감\n당기상각\n기말장부가액\n비고\n증가\n감소\n토지\n자가\n용인\n3,391,420\n3,391,420\n건물\n자가\n용인\n20,814,851\n566,198\n479,707\n20,901,342\n기계장치\n자가\n용인\n769,441\n12,620,661\n1,639,755\n11,750,347\n공구기구\n자가\n용인\n278,297\n61,797\n216,500\n집기비품\n자가\n용인\n31,534\n8,332\n5,684\n34,182\n합계\n25,285,543\n13,195,191\n2,186,943\n36,293,791\n(2) 설비의 신설ㆍ매입 계획 등\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0(단위 : 억원, 부가세별도)\n사업부문\n투자대상자산\n총투자예정액\n기투자액\n향후\n비 고\n투자계획액\n제조\n첩부제공장리모델링 및 증축\n180\n169\n11\n기계장치(플라스마 전고기외)\n127\n119\n8\n\u3000\n\xa0 \xa0합 \xa0계\u3000\n307\n288\n19\n\xa0 \xa0 \u3000\n']"
